Hodogaya Chemical Co., Ltd.

Mochida Pharmaceutical Co., Ltd.

Ikuo Kimura

Masami Ito

Masaya Tojo

Motonori Tsuji

Kanae Hiraishi

Masafumi Asakai

Takeshi Yamamoto

Ichiro Yamamoto

Tetsuya Yoshida

Hidenori Mochizuki

Akihiro Imai

Masaki Okubo

Masaya Tojou

Tetsuyuki Nakase

Takeshi Niho

To provide a charge control agent and a toner having a superior charging characteristic. A charge control agent containing a bis-phthalimide derivative represented by formula. Thus, it is possible to provide a safe, negative chargeability charge control agent with which the rate of rise of the charge can be increased, and which has a high charging amount and poses no problem in terms of waste regulations. Furthermore, it is possible to provide a negatively chargeable toner (and particularly, a negatively chargeable polymerized toner) for electrostatic image development which uses this charging control agent and has a superior charging characteristic.

Charge control agent and toner using same

A charge control agent comprises a barbituric acid derivative represented by the following general formula (1): 

Charge control agent and toner using the same

The present invention provides a charge control agent containing, as an active substance(s), one or two or more thiazolidinedione derivatives represented by the following formula (1), where Rrepresents a hydrogen atom, etc.; Rrepresents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms which may have a substituent, etc.; Rto R, which may be identical to or different from each other, represent a hydrogen atom, a chlorine atom, a linear or branched alkyl group having 1 to 8 carbon atoms which may have a substituent, etc., and may be joined to each other to form a ring; and V, W, X, Y and Z represent a carbon atom or a nitrogen atom, and 0 to 3 of any of V, W, X, Y and Z are nitrogen atoms which do not have the substituents of Rto R.

This invention relates to a novel compound which is useful as a drug in preventing and/or treating peptic ulcer-related diseases, to a production process thereof and to a pharmaceutical composition containing the same. Particularly, it provides a compound which has a specified substituted alkynylpyrazine nucleus or a specified substituted alkynylquinoxaline nucleus, represented by the following formula (I) ##STR1## wherein A is represented by the following formula (II) or (III) ##STR2## and R.sup.1 is represented by the following formula (IV), ##STR3## and the salts thereof, a production process thereof and a pharmaceutical composition containing the same. The inventive compound is useful as a drug in preventing and/or treating peptic ulcer-related diseases.

Antiulcer compounds having a substituted alkynyl or quinoxaline nucleus

Growing community of inventors

Ibaraki, Japan

Ikuo Kimura